Table 3.

Summary of grade 3, 4 or 5 AEs possibly, probably or definitely related to alemtuzumab therapy in patients with ATL (N = 29)

Adverse Event	Grade 3 No (%)	Grade 4 No (%)
Hematologic:
• Leukopenia	• 12 (41)	• 5 (17)
• Lymphocytopenia	• 17 (59)	• 0
• Neutropenia	• 9 (31)	• 1 (3)
• Anemia	• 7 (24)	• 0
• Thrombocytopenia	• 3 (10)	• 0
Hepatic:
• Alkaline phosphatase	• 1 (3)	• 0
• Gamma-glutamyl transpeptidase	• 1 (3)	• 0
• Bilirubin	• 1 (3)	• 0
• Hypoalbuminemia	• 2 (7)	• 0
Metabolic:
• Creatinine phosphokinase	• 1 (3)	• 0
• Hypercalcemia	• 1 (3)	• 0
• Hypocalcemia	• 1 (3)	• 0
• Hypokalemia	• 1 (3)	• 0
• Hypophosphatemia	• 1 (3)	• 0
Allergy Immunology:
• Allergic reaction	• 1 (3)	• 0
Cardiovascular:
• Vasovagal episode	• 2 (7)	• 0
Hypotension	• 3 (10)	• 0
Constitutional symptoms:
• Fever in the absence of neutropenia	• 3 (10)	• 0
Pulmonary:
• Pulmonary infiltrates	• 1 (3)	• 0
• Pulmonary hypoxia	• 2 (7)	• 0
Ocular/Visual:
• Blurred vision	• 1 (3)	• 0
• Photophobia	• 1 (3)	• 0
• (other) Uveitis	• 1 (3	• 0
Endocrine:
• Hyperthyroidism	• 1 (3)	• 0
Dermatological:
• Rash, desquamation	• 1 (3)	• 0
Infection:
• With Grade 3 or 4 neutropenia	• 2 (7)	• 0
• Without Grade 3 or 4 neutropenia	• 2 (7)	• 0

Abbreviations

AE adverse events